Skip to main content

Grafa News and Videos — Page 1096

Grafa Headlines

Latest

Grafa

Amneal reports positive Phase 4 data for CREXONT in Parkinson’s treatment

Amneal Pharmaceuticals (NASDAQ:AMRX) has announced encouraging interim data from the Phase 4 ELEVATE-PD clinical trial, which evaluates the efficacy and safety of CREXONT (carbidopa and levodopa) extended-release capsules in patients living with Parkinson’s disease.

Read more: Amneal reports positive Phase 4 data for CREXONT in Parkinson’s treatment
Grafa
Retail

G-III Apparel earnings lifted by one-time tariff benefit; guidance raised

G-III Apparel Group (NASDAQ:GIII), the owner and licensee of a diverse portfolio of fashion brands, reported its financial results for the first quarter of fiscal 2027, highlighting the impact of a significant regulatory refund alongside its strategic pivot toward new brand ownership.

Read more: G-III Apparel earnings lifted by one-time tariff benefit; guidance raised
Grafa

Gilead and Lakefront Biotherapeutics complete $1.68B acquisition of Ouro Medicines

Gilead Sciences (NASDAQ:GILD) and Lakefront Biotherapeutics (NASDAQ:LKFT) have finalized the acquisition of Ouro Medicines, a strategic move designed to bolster their respective inflammation and immunology portfolios with next-generation T cell engager therapies.

Read more: Gilead and Lakefront Biotherapeutics complete $1.68B acquisition of Ouro Medicines

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift